Nasal and Ocular Immunization with Bacteriophage Virus-like Particle Vaccines Elicits Distinct Systemic and Mucosal Antibody Profiles
Open Access
Abstract
Background/Objectives: Intramuscular immunization elicits systemic IgG and is the primary route of vaccine administration in humans. However, there is growing interest in utilizing other routes of administration to tailor antibody profiles, increase immunity at primary sites of infection, simplify administration, and eliminate needle waste. Here, we investigated the antibody profiles elicited by immunization with bacteriophage virus-like particle vaccine platforms at various routes of administration. Methods: We chose two model bacteriophage vaccines for investigation: bacteriophage MS2 virus-like particles (VLPs) recombinantly displaying a short, conserved peptide from Chlamydia trachomatis major outer membrane protein (MS2) and bacteriophage Qβ VLPs displaying oxycodone through chemical conjugation (Qβ). We comprehensively characterized the antibodies elicited systemically and at various mucosal sites when the vaccines were administered intramuscularly, intranasally or periocularly with or without an intramuscular prime using various prime/boost schemes. Results: Intranasal and periocular immunization elicited robust mucosal and systemic IgA responses for both MS2 and Qβ. The intramuscular prime followed by intranasal or periocular boosts elicited broad antibody responses, and increased antibodies titers at certain anatomical sites. Conclusions: These findings demonstrate the tractability of bacteriophage VLP-based vaccines in generating specific antibody profiles based on the prime–boost regimen and route of administration.Keywords
Funding Information
- NIAID (F31 AI179064, T32 AI007538-19, R01 AI166360, F31 DA059236, UL1 TR001449, R25CA247794, R25CA247794)
- NIDA (F31 AI179064, T32 AI007538-19, R01 AI166360, F31 DA059236, UL1 TR001449, R25CA247794, R25CA247794)
- NCATS (F31 AI179064, T32 AI007538-19, R01 AI166360, F31 DA059236, UL1 TR001449, R25CA247794, R25CA247794)
- National Computational Infrastructure (F31 AI179064, T32 AI007538-19, R01 AI166360, F31 DA059236, UL1 TR001449, R25CA247794, R25CA247794)
- National Computational Infrastructure (F31 AI179064, T32 AI007538-19, R01 AI166360, F31 DA059236, UL1 TR001449, R25CA247794, R25CA247794)
This publication has 21 references indexed in Scilit:
- Respiratory mucosal vaccines: Applications, delivery strategies and design considerationsBiomedicine & Pharmacotherapy, 2025
- A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the bloodVaccine, 2023
- Bacteriophage Virus-Like Particles: Platforms for Vaccine Design2023
- Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathologyVaccine, 2022
- Mucosal vaccines: Strategies and challengesImmunology Letters, 2020
- Detection of immunoglobulin (Ig) A antibodies against porcine epidemic diarrhea virus (PEDV) in fecal and serum samplesMethodsX, 2015
- Efficient induction of mucosal and systemic immune responses by virus‐like particles administered intranasally: implications for vaccine designEuropean Journal of Immunology, 2007
- Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adultsJournal of Allergy and Clinical Immunology, 2006
- A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicityEuropean Journal of Immunology, 2005
- A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responsesVaccine, 2002